ライフサイエンスコーパス: peripheral arterial disease

1 rization, angina, stroke, heart failure, and peripheral arterial disease).

2 riables (C) (smoking, diabetes mellitus, and peripheral arterial disease).

3 CVD included CHD, stroke, heart failure, and peripheral arterial disease.

4 in ischemia-induced angiogenesis, such as in peripheral arterial disease.

5 bility could be extended to patients without peripheral arterial disease.

6 ther the WIQ can be used in patients without peripheral arterial disease.

7 ith diabetes, tobacco use, heart failure, or peripheral arterial disease.

8 lar morbidity and mortality in patients with peripheral arterial disease.

9 ent-resistant hypertension, preeclampsia, or peripheral arterial disease.

10 chemia is a life-threatening complication of peripheral arterial disease.

11 oke, nephropathy, ischemic heart disease and peripheral arterial disease.

12 t limb salvage rates in patients with severe peripheral arterial disease.

13 ial femoral artery of diabetic patients with peripheral arterial disease.

14 tudied and validated therapy for symptomatic peripheral arterial disease.

15 ative to PTA for treatment of infrapopliteal peripheral arterial disease.

16 ry heart disease, heart failure, stroke, and peripheral arterial disease.

17 heart disease, cerebrovascular disease, and peripheral arterial disease.

18 with less functional decline in persons with peripheral arterial disease.

19 th less functional decline among people with peripheral arterial disease.

20 ations for clinical imaging in patients with peripheral arterial disease.

21 aemorrhage, carotid dissection, and, rarely, peripheral arterial disease.

22 onal decline in persons with lower-extremity peripheral arterial disease.

23 ovascular and surgical revascularization for peripheral arterial disease.

24 , and depression worsens vascular outcome in peripheral arterial disease.

25 ponses are impaired in elderly patients with peripheral arterial disease.

26 utive patients underwent PER for symptomatic peripheral arterial disease.

27 schemia, such as coronary artery disease and peripheral arterial disease.

28 ed as coronary heart disease, stroke, and/or peripheral arterial disease.

29 diseases such as coronary artery disease and peripheral arterial disease.

30 ) is a widely utilized measure for detecting peripheral arterial disease.

31 o 2.69 for stroke, and from 1.66 to 4.28 for peripheral arterial disease.

32 o 1.53 for stroke, and from 0.61 to 1.58 for peripheral arterial disease.

33 y partially mediate the effect of smoking on peripheral arterial disease.

34 progestin did not confer protection against peripheral arterial disease.

35 factor may provide a novel approach to treat peripheral arterial disease.

36 between blood levels of lead and cadmium and peripheral arterial disease.

37 her confounders in patients with and without peripheral arterial disease.

38 ence functioning in persons with and without peripheral arterial disease.

39 54 persons with claudication attributable to peripheral arterial disease.

40 interventions in patients with asymptomatic peripheral arterial disease.

41 ischemic heart disease, ischemic stroke, and peripheral arterial disease.

42 al limb ischemia represents the end stage of peripheral arterial disease.

43 reperfuse the limbs of certain patients with peripheral arterial disease.

44 s (46% of possible matches), 95% of whom had peripheral arterial disease.

45 s in patients with stable coronary artery or peripheral arterial disease.

46 tection of disease and monitoring therapy in peripheral arterial disease.

47 ients with stable coronary artery disease or peripheral arterial disease.

48 tients, women, and patients with diabetes or peripheral arterial disease.

49 ld yield the most efficacious treatments for peripheral arterial disease.

50 t-reported walking performance developed for peripheral arterial disease.

51 t disease (CHD), cerebrovascular disease and peripheral arterial disease.

52 ipheral blood flow in selected patients with peripheral arterial diseases.

53 g 0.91 [95% CI 0.86-0.98]) and strongest for peripheral arterial disease (1.23 [1.20-1.27]).

54 presentation, of which the most common were peripheral arterial disease (16.2%, n=992) and heart fai

55 e patients with stent occlusion or stenoses, peripheral arterial disease (ABI <1.0), symptomatic card

56 etes was strongly positively associated with peripheral arterial disease (adjusted cause-specific haz

57 pe 2 diabetes was positively associated with peripheral arterial disease (adjusted HR 2.98 [95% CI 2.

58 ovascular disease mortality and one study on peripheral arterial disease).All but one study reported

59 ion of serum selenium with the prevalence of peripheral arterial disease among 2,062 US men and women

60 This analysis evaluates clinical peripheral arterial disease among generally healthy wome

61 l CVD events (coronary, cerebrovascular, and peripheral arterial disease and heart failure).

62 ng is critical for blood flow restoration in peripheral arterial disease and is triggered by increasi

63 Ischemia (CLI) is the most advanced stage of peripheral arterial disease and is usually treated with

64 ociation between this noninvasive measure of peripheral arterial disease and mortality risk.

65 ncreased in a range of conditions, including peripheral arterial disease and myocardial infarction, w

66 in the response to ischemia associated with peripheral arterial disease and myocardial infarction.

67 er peripheral arterial revascularization for peripheral arterial disease and to assess whether readmi

68 VD, defined as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart fail

69 0.722 for ADA HbA1c clinical categories for peripheral arterial disease, and 0.683 for ADA fasting g

70 l duration, the absence of beta-blocker use, peripheral arterial disease, and a deeper prosthesis ins

71 rt failure with preserved ejection fraction, peripheral arterial disease, and abdominal aortic aneury

72 nary heart disease, cerebrovascular disease, peripheral arterial disease, and all-cause cardiovascula

73 onic kidney disease, cardiovascular disease, peripheral arterial disease, and all-cause mortality tha

74 are performed in patients with diabetes and peripheral arterial disease, and at least 25% require su

75 von Willebrand factor, alcohol consumption, peripheral arterial disease, and carotid artery wall thi

76 r disease, including coronary heart disease, peripheral arterial disease, and cerebrovascular disease

77 Hypertension, myocardial infarction, peripheral arterial disease, and impaired renal function

78 CAC] scores, carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity).

79 ith reduced risks of coronary heart disease, peripheral arterial disease, and stroke.

80 eria included diabetes mellitus, symptomatic peripheral arterial disease, and superficial femoral art

81 hypertension, previous heart failure, MI, or peripheral arterial disease; and who received coronary a

82 patients more often had a history of stroke, peripheral arterial disease, angina, heart failure, diab

83 eart failure after myocardial infarction and peripheral arterial disease are predominant, devastating

84 Heart failure and peripheral arterial disease are the most common initial

85 options for the treatment of lower extremity peripheral arterial disease are typified with diminished

86 ional decline in people with lower extremity peripheral arterial disease are unknown.

87 ongly associated with coronary, cerebral and peripheral arterial disease, as well as with microangiop

88 CLI is an advanced form of peripheral arterial disease associated with nonhealing a

89 erosclerosis (ie, risk factors, coronary and peripheral arterial disease, asymptomatic carotid stenos

90 r the treatment of patients with symptomatic peripheral arterial disease because they are associated

91 Rates of evaluation for peripheral arterial disease before amputation were low,

92 rization, angina, stroke, heart failure, and peripheral arterial disease), but less effective in prev

93 e and blood flow in an experimental model of peripheral arterial disease, by exploiting fluorescence

94 and cardiovascular risk factors, the ORs of peripheral arterial disease comparing quartiles 2 to 4 o

95 The fully adjusted odds ratios for peripheral arterial disease comparing selenium quartiles

96 cular (cerebrovascular, coronary artery, and peripheral arterial diseases) complications.

97 A diagnosis of peripheral arterial disease confers an increased risk of

98 ction, pre-procedural myocardial infarction, peripheral arterial disease, congestive heart disease, r

99 ary artery disease, cerebrovascular disease, peripheral arterial disease, congestive heart failure, m

100 Further they had more peripheral arterial disease, coronary artery disease, ca

101 y of autologous cell therapy for intractable peripheral arterial disease/critical limb ischemia.

102 age-, sex-, and race-adjusted prevalence of peripheral arterial disease decreased with increasing se

103 rd quantitative imaging approach to evaluate peripheral arterial disease does not exist.

104 r, rheumatic heart disease, aortic aneurysm, peripheral arterial disease, endocarditis, and all other

105 Peripheral arterial disease epidemiology and/or manageme

106 monary disease, acute myocardial infarction, peripheral arterial disease, epilepsy, substance abuse,

107 ace, renal disease, diabetes mellitus, known peripheral arterial disease, evaluation by a vascular sp

108 disease, 117 cerebrovascular disease, and 98 peripheral arterial disease events.

109 1 years) and 13 patients suspected of having peripheral arterial disease (five men; mean age, 67 year

110 vascular disease (coronary artery disease or peripheral arterial disease) followed from 1997 to 2009,

111 The OR of peripheral arterial disease for current smokers compared

112 Isner, the field of cell-based therapies for peripheral arterial disease has been in a state of conti

113 e, but its clinical significance in advanced peripheral arterial disease has not been evaluated.

114 shed CV disease, including HTN, HF, CHD, and peripheral arterial disease, have a better prognosis com

115 1.5-2.0) for stable angina, ischemic stroke, peripheral arterial disease, heart failure, and cardiac

116 risk factors include advanced age, smoking, peripheral arterial disease, high blood pressure, corona

117 tio [HR], 0.77; 95% CI, 0.62-0.94; P = .01), peripheral arterial disease (HR, 0.65; 95% CI, 0.49-0.87

118 se (HR, 0.82), heart failure (HR, 0.84), and peripheral arterial disease (HR, 0.85).

119 hiectomy was noted for fractures (HR, 1.80), peripheral arterial disease (HR, 2.25), venous thromboem

120 95% confidence interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI: 1.72 to 2

121 myocardial infarction (HR=1.75, P=0.02), and peripheral arterial disease (HR=2.01, P=0.01).

122 pulmonary disease, coronary artery disease, peripheral arterial disease, hypertension, pulmonary hyp

123 ischemia may contribute to worse outcomes of peripheral arterial disease in patients with diabetes me

124 e associated with an increased prevalence of peripheral arterial disease in the general US population

125 The age-adjusted prevalence of peripheral arterial disease in the US population has bee

126 The age-adjusted prevalence of peripheral arterial disease in the US population was est

127 Surgical treatment options for peripheral arterial disease include angioplasty, endarte

128 The clinical consequences of occlusive peripheral arterial disease include intermittent claudic

129 The clinical consequences of occlusive peripheral arterial disease include pain on walking (cla

130 The prevalence of peripheral arterial disease increases with the age of th

131 Peripheral arterial disease is a common disease that has

132 Peripheral arterial disease is a major complication of d

133 Peripheral arterial disease is a manifestation of system

134 Peripheral arterial disease is associated with adverse c

135 By contrast, the prevalence of peripheral arterial disease is increased from five- to 1

136 Peripheral arterial disease is largely considered to be

137 Because peripheral arterial disease is most commonly caused by a

138 Peripheral arterial disease is one manifestation of syst

139 pulation ages, the overall population having peripheral arterial disease is predicted to rise.

140 he evolution of interventional treatments of peripheral arterial disease is progressing at a dizzying

141 taneous interventions for lifestyle-limiting peripheral arterial disease is unknown.

142 self as acute coronary syndrome, stroke, and peripheral arterial diseases, is a chronic progressive i

143 worsen the prognosis of myocardial ischemia, peripheral arterial disease, ischemic stroke, etc.

144 We hypothesized that in peripheral arterial disease, maladaptive changes in VEGF

145 hen treated with atorvastatin, patients with peripheral arterial disease may experience improvement i

146 Treatment of peripheral arterial diseases may be distinguished into c

147 For peripheral arterial disease, men with PLMI >/=30 compare

148 thesis in conditions that simulate tumor and peripheral arterial disease microenvironment.

149 In a mouse hindlimb ischemia model of peripheral arterial disease, MITCH-PEG co-delivery of hi

150 pes) (effective sample size [n(e)] = 9,396); peripheral arterial disease (n(e) = 5,215); abdominal ao

151 40,258; cerebrovascular disease, n = 18,843; peripheral arterial disease, n = 8273) or 3 or more risk

152 (Comprehensive Magnetic Resonance of Peripheral Arterial Disease; NCT00587678).

153 ce interval [CI], 0.31-0.45; P=5.5*10(-26)], peripheral arterial disease (odds ratio 0.42; 95% CI, 0.

154 Patients with peripheral arterial disease often undergo peripheral end

155 artery disease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factor

156 hrombotic (coronary, cerebrovascular, and/or peripheral arterial) disease or multiple atherothromboti

157 pertension (OR, 0.58; 95% CI, 0.43-0.78) and peripheral arterial disease (OR, 0.43; 95% CI, 0.22-0.85

158 1.7), male gender (OR, 1.6), and history of peripheral arterial disease (OR, 1.6).

159 a-blocker use (OR, 0.12; 95% CI, 0.03-0.45), peripheral arterial disease (OR, 6.36; 95% CI, 1.56-25.8

160 levels but without coronary artery disease, peripheral arterial disease, or diabetes mellitus.

161 option for patients with renal dysfunction, peripheral arterial disease, or following a brief P2Y12-

162 e patients with prior myocardial infarction, peripheral arterial disease, or stroke.

163 Patients with diabetes, heart failure, peripheral arterial disease, or tobacco use had the larg

164 rtality, including among individuals without peripheral arterial disease (P<0.001).

165 diabetes (P<0.0001), hypertension (P<0.001), peripheral arterial disease (P=0.0002), smoking (P<0.000

166 ves (adjusted chi-square=38.3, p <0.001) and peripheral arterial disease (PAD) (adjusted chi-square=1

167 eases, the only significant finding was with peripheral arterial disease (PAD) (OR = 5.11, p < 0.001)

168 Peripheral arterial disease (PAD) affects 5 million peop

169 ardiovascular disease (CVD) risk factors and peripheral arterial disease (PAD) after adjustment for t

170 risk factors explain the high prevalence of peripheral arterial disease (PAD) among African American

171 2 diabetes respond poorly to treatments for peripheral arterial disease (PAD) and are more likely to

172 lthough exertional leg pain is a hallmark of peripheral arterial disease (PAD) and can occur in perso

173 els, inorganic arsenic exposure is linked to peripheral arterial disease (PAD) and cardiovascular dis

174 Peripheral arterial disease (PAD) and diabetes are both

175 eadmill walking performance in patients with peripheral arterial disease (PAD) and intermittent claud

176 o determine differences in the prevalence of peripheral arterial disease (PAD) and its associations w

177 ent study were to describe the prevalence of peripheral arterial disease (PAD) and its effects on pro

178 Peripheral arterial disease (PAD) and osteoporosis are c

179 The ABI is used to diagnose peripheral arterial disease (PAD) and to identify those

180 rs that regulate angiogenesis are altered in peripheral arterial disease (PAD) and whether these fact

181 m a vascular cohort with a history of either peripheral arterial disease (PAD) and/or other cardiovas

182 Patients with peripheral arterial disease (PAD) are at a high risk for

183 Data on the natural history of peripheral arterial disease (PAD) are scarce and are foc

184 aimed to investigate the pathophysiology of peripheral arterial disease (PAD) by examining magnetic

185 Peripheral arterial disease (PAD) caused by occlusive at

186 Peripheral arterial disease (PAD) causes significant mor

187 HF), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent

188 Importance: Patients with concomitant peripheral arterial disease (PAD) experience worse cardi

189 Patients with peripheral arterial disease (PAD) have high rates of adv

190 Men and women with lower extremity peripheral arterial disease (PAD) have higher levels of

191 ain the higher prevalence of lower-extremity peripheral arterial disease (PAD) in black adults.

192 vious studies have indicated higher rates of peripheral arterial disease (PAD) in blacks than in non-

193 Cadmium has been associated with peripheral arterial disease (PAD) in cross-sectional stu

194 Homocysteine levels are associated with peripheral arterial disease (PAD) in observational studi

195 wn about the epidemiology of lower-extremity peripheral arterial disease (PAD) in persons with renal

196 index (BMI; weight (kg)/height (m)(2)) with peripheral arterial disease (PAD) in prior studies may r

197 scular reactivity and functional capacity in peripheral arterial disease (PAD) in small, short-term s

198 tion and medical management of patients with peripheral arterial disease (PAD) in the last 1 to 2 yea

199 Peripheral arterial disease (PAD) is a chronic, lifestyl

200 Peripheral arterial disease (PAD) is a clinical conditio

201 Peripheral arterial disease (PAD) is a clinical manifest

202 Peripheral arterial disease (PAD) is a costly source of

203 Peripheral arterial disease (PAD) is a subclinical measu

204 Peripheral arterial disease (PAD) is an important cardio

205 Lower-extremity peripheral arterial disease (PAD) is associated with dec

206 Peripheral arterial disease (PAD) is associated with sig

207 Peripheral arterial disease (PAD) is caused by atheroscl

208 Peripheral arterial disease (PAD) is common but commonly

209 The prevalence of peripheral arterial disease (PAD) is increasing worldwid

210 It was hypothesized that peripheral arterial disease (PAD) is less frequent after

211 iovascular disease, but its association with peripheral arterial disease (PAD) is unclear.

212 PURPOSE OF REVIEW: Peripheral arterial disease (PAD) is underdiagnosed, und

213 oke, but whether it predicts lower extremity peripheral arterial disease (PAD) is unknown.

214 le of inflammation in the pathophysiology of peripheral arterial disease (PAD) is well established, t

215 ides an advantageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

216 ides an advantageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

217 in patients with and without lower-extremity peripheral arterial disease (PAD) over three-year follow

218 etics plays an important role in determining peripheral arterial disease (PAD) pathology, which cause

219 I] 1.0 +/- 0.1, mean age 30 +/- 7 years); 2) peripheral arterial disease (PAD) patients (n = 12; mean

220 gnetic resonance spectroscopy in symptomatic peripheral arterial disease (PAD) patients compared with

221 in gastrocnemius biopsies from patients with peripheral arterial disease (PAD) predict mortality rate

222 Genetic determinants of peripheral arterial disease (PAD) remain largely unknown

223 rmining the amputation risk in patients with peripheral arterial disease (PAD) remains difficult.

224 STF) recently released an update to its 1996 Peripheral Arterial Disease (PAD) Screening Recommendati

225 Peripheral arterial disease (PAD) was defined by ankle b

226 blood and urine cadmium concentrations with peripheral arterial disease (PAD) were evaluated by usin

227 rmined whether patients with lower-extremity peripheral arterial disease (PAD) who are more physicall

228 the association of progressive versus stable peripheral arterial disease (PAD) with the risk of futur

229 cise nor strength training for patients with peripheral arterial disease (PAD) without intermittent c

230 hypothesized that women with lower extremity peripheral arterial disease (PAD) would have greater mob

231 ABI categories were defined: <0.90 (definite peripheral arterial disease (PAD)), 0.90-0.99 (borderlin

232 l nervous system, but their association with peripheral arterial disease (PAD), a high-prevalence vas

233 CRP (P< or =0.05) and increasing severity of peripheral arterial disease (PAD), after adjustment for

234 sessed plasma-based factors as predictors of peripheral arterial disease (PAD), and comparative data

235 Among individuals with lower-extremity peripheral arterial disease (PAD), specific leg symptoms

236 Several risk factors for atherosclerotic peripheral arterial disease (PAD), such as dyslipidemia,

237 the management of patients with established peripheral arterial disease (PAD), the prevalence of PAD

238 In participants with peripheral arterial disease (PAD), we determined whether

239 R angiography for suspected or known chronic peripheral arterial disease (PAD), with contrast materia

240 al ankle-brachial index (ABI) and those with peripheral arterial disease (PAD).

241 higher mortality rates in men and women with peripheral arterial disease (PAD).

242 ct cardiovascular mortality in patients with peripheral arterial disease (PAD).

243 atherosclerosis in patients with concomitant peripheral arterial disease (PAD).

244 uscle perfusion in subjects with progressive peripheral arterial disease (PAD).

245 The 666 participants included 412 with peripheral arterial disease (PAD).

246 quality of life in asymptomatic persons with peripheral arterial disease (PAD).

247 rction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).

248 mes in a cohort of patients with symptomatic peripheral arterial disease (PAD).

249 alf strength in persons with lower extremity peripheral arterial disease (PAD).

250 ility loss among persons with versus without peripheral arterial disease (PAD).

251 onal impairment in patients with and without peripheral arterial disease (PAD).

252 des a promising avenue for the management of peripheral arterial disease (PAD).

253 ing ischemia to lower limbs in patients with peripheral arterial disease (PAD).

254 ar events and amputation among patients with peripheral arterial disease (PAD).

255 is frequently performed for the treatment of peripheral arterial disease (PAD).

256 promote physiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vas

257 The impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular di

258 ETHODS AND The study population included 203 peripheral arterial disease participants who underwent v

259 Peripheral arterial disease patients included those with

260 2 improves treadmill exercise performance in peripheral arterial disease patients with claudication-l

261 rticularly important for the large number of peripheral arterial disease persons without access to su

262 oronary artery disease, limb ischemia due to peripheral arterial disease, pressure-overload heart fai

263 In spline regression models, peripheral arterial disease prevalence decreased with in

264 Peripheral arterial disease prevalence ranged from 3.1%

265 orbidities including hypertension, diabetes, peripheral arterial disease, previous myocardial infarct

266 e, diabetes mellitus, hypertension, smoking, peripheral arterial disease, previous stroke, previous c

267 s without clinical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD r

268 3 US Medicare patients who underwent a major peripheral arterial disease-related amputation during th

269 nding on vascular care and regional rates of peripheral arterial disease-related amputation.

270 ulmonary disease, calcified ascending aorta, peripheral arterial disease, renal failure, and previous

271 presentation, the most common of which were peripheral arterial disease (reported in 992 [16.2%] of

272 Peripheral Arterial Disease Research Coalition (Europe).

273 Atherosclerosis in the form of peripheral arterial disease results in significant morbi

274 myocardium, atrial fibrillation, aortic and peripheral arterial disease, rheumatic heart disease, an

275 and baseline characteristics with regard to peripheral arterial disease risk.

276 at interventions to prevent mobility loss in peripheral arterial disease should focus on reversing pa

277 roke, chronic obstructive pulmonary disease, peripheral arterial disease, smoking, diabetes, renal fa

278 pecificity, 96%; LR, 3.1 [95% CI, 2.0-4.7]), peripheral arterial disease (specificity, 97%; LR, 2.7 [

279 ional, and surgical therapy for coronary and peripheral arterial disease, the burden of these illness

280 are recommended for secondary prevention in peripheral arterial disease, their effectiveness in CLI

281 a risk equivalent condition for coronary and peripheral arterial diseases, these findings create a pa

282 ion procedures is increased in patients with peripheral arterial disease, thus increasing the inciden

283 f myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg

284 AND Three hundred seventy participants with peripheral arterial disease underwent baseline measureme

285 Any fractures, peripheral arterial disease, venous thromboembolism, car

286 Peripheral arterial disease was defined as an ankle brac

287 Peripheral arterial disease was defined as an ankle-brac

288 Hospitalization for peripheral arterial disease was infrequent, with annuali

289 serum selenium levels and the prevalence of peripheral arterial disease was not statistically signif

290 icenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment w

291 na, recent coronary artery bypass graft, and peripheral arterial disease were associated with prescri

292 ntrolled trial, 76 patients with symptomatic peripheral arterial disease were randomized 2:1 to recei

293 left ventricular ejection fraction <20%, and peripheral arterial disease were significant predictors

294 Treatment options for diabetic patients with peripheral arterial disease when revascularization is no

295 effect on angina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic bl

296 igger of chronic coronary, intracranial, and peripheral arterial diseases, which together account for

297 unweighted hospitalizations of patients with peripheral arterial disease who had peripheral arterial

298 More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arter

299 andomized trial in symptomatic patients with peripheral arterial disease who underwent endovascular t

300 ong 61 969 hospitalizations of patients with peripheral arterial disease who were discharged alive af